Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Infections in patients diagnosed with multiple sclerosis: A multi-database study
Rebecca Persson, S. Lee, Marianne Ulcickas Yood, et al.
Multiple Sclerosis and Related Disorders (2020) Vol. 41, pp. 101982-101982
Closed Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Neurological and Neuropsychiatric Impacts of COVID-19 Pandemic
Devlina Roy, Ritwik Ghosh, Souvik Dubey, et al.
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques (2020) Vol. 48, Iss. 1, pp. 9-24
Open Access | Times Cited: 218
COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?
Luigi Ferini‐Strambi, Maria Salsone
Journal of Neurology (2020) Vol. 268, Iss. 2, pp. 409-419
Open Access | Times Cited: 150
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Stephen L. Hauser, Ludwig Kappos, Xavier Montalbán, et al.
Neurology (2021) Vol. 97, Iss. 16
Open Access | Times Cited: 123
COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response
Ana Zabalza, Simón Cárdenas‐Robledo, Paula Tagliani, et al.
European Journal of Neurology (2020) Vol. 28, Iss. 10, pp. 3384-3395
Closed Access | Times Cited: 131
Neurological complications associated with Covid‐19; molecular mechanisms and therapeutic approaches
Mohammad Mahboubi Mehrabani, Mohammad Sobhan Karvandi, Pedram Maafi, et al.
Reviews in Medical Virology (2022) Vol. 32, Iss. 6
Open Access | Times Cited: 47
Multiple Sclerosis, Disease-Modifying Therapies, and Infections
Annette Langer‐Gould, Jessica B. Smith, Edlin Gonzales, et al.
Neurology Neuroimmunology & Neuroinflammation (2023) Vol. 10, Iss. 6
Open Access | Times Cited: 25
Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases
Riccardo Nistri, Elena Barbuti, Virginia Rinaldi, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 49
Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases
N. Oksbjerg, Susanne Dam Nielsen, Morten Blinkenberg, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 52, pp. 102988-102988
Open Access | Times Cited: 45
Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
Lutz Achtnichts, Barbara Jakopp, Michael Oberle, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1470-1470
Open Access | Times Cited: 44
Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis
Brandi Vollmer, Andrew B. Wolf, Stefan Sillau, et al.
Frontiers in Neurology (2022) Vol. 12
Open Access | Times Cited: 35
Infections in patients with multiple sclerosis: A national cohort study in Sweden
Anna Castelo‐Branco, Flaminia Chiesa, Simona Conte, et al.
Multiple Sclerosis and Related Disorders (2020) Vol. 45, pp. 102420-102420
Open Access | Times Cited: 45
Genetic Diversity of SARS-CoV2 and Environmental Settings: Possible Association with Neurological Disorders
Sharifa Hasana, Md. Farhad Hossain, Maroua Jalouli, et al.
Molecular Neurobiology (2021) Vol. 58, Iss. 5, pp. 1917-1931
Open Access | Times Cited: 35
Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era
Patricia K. Coyle, Anne R. Gocke, Megan Vignos, et al.
Advances in Therapy (2021) Vol. 38, Iss. 7, pp. 3550-3588
Open Access | Times Cited: 34
Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
Nabil Seery, Sifat Sharmin, Vivien Li, et al.
CNS Drugs (2021) Vol. 35, Iss. 8, pp. 907-918
Open Access | Times Cited: 33
MS treatment de-escalation: review and commentary
Krzysztof Selmaj, Hans–Peter Hartung, Marcin P. Mycko, et al.
Journal of Neurology (2024) Vol. 271, Iss. 10, pp. 6426-6438
Open Access | Times Cited: 5
MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis
Bassem Yamout, Magd Zakaria, Jihad Inshasi, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 56, pp. 103225-103225
Open Access | Times Cited: 31
Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review
Fardin Nabizadeh, Elham Ramezannezhad, Kimia Kazemzadeh, et al.
Journal of Clinical Neuroscience (2022) Vol. 104, pp. 118-125
Open Access | Times Cited: 22
An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations
Bülent Kantarcıoğlu, Omer Iqbal, Joseph M. Lewis, et al.
Clinical and Applied Thrombosis/Hemostasis (2022) Vol. 28
Open Access | Times Cited: 21
Risk of serious infections in multiple sclerosis patients by disease course and disability status: Results from a Swedish register-based study
Judith S. Brand, Kelsi A Smith, Fredrik Piehl, et al.
Brain Behavior & Immunity - Health (2022) Vol. 22, pp. 100470-100470
Open Access | Times Cited: 21
Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case–control study in an English population-based cohort
Benjamin Meir Jacobs, Pooja Tank, Jonathan P. Bestwick, et al.
Journal of Neurology (2023) Vol. 271, Iss. 1, pp. 241-253
Open Access | Times Cited: 10
Tackling Infectious Diseases in the Caribbean and South America: Epidemiological Insights, Antibiotic Resistance, Associated Infectious Diseases in Immunological Disorders, Global Infection Response, and Experimental Anti-Idiotypic Vaccine Candidates Against Microorganisms of Public Health Importance
Angel A Justiz-Vaillant, Sachin Soodeen, Darren Gopaul, et al.
Microorganisms (2025) Vol. 13, Iss. 2, pp. 282-282
Open Access
Rituximab for people with multiple sclerosis
Graziella Filippini, Jera Kruja, Cinzia Del Giovane
Cochrane library (2025) Vol. 2025, Iss. 3
Open Access
Trauma Burden Affected People with Multiple Sclerosis During SARS-CoV-2 Pandemic
Felicita Heidler, Michael Hecker, Niklas Frahm, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 8, pp. 2665-2665
Open Access
Tetanus and Diphtheria Toxoid-Containing Vaccine in Multiple Sclerosis Patients: A Real-World Prospective, Open-Label, Multi-Centre Study
Alexander Winkelmann, Emil C. Reisinger, Katharina Boden, et al.
Vaccines (2025) Vol. 13, Iss. 5, pp. 451-451
Open Access
Multiple sclerosis and COVID‐19: The Swedish experience
Anne‐Marie Landtblom, Shala Ghaderi Berntsson, Inger Boström, et al.
Acta Neurologica Scandinavica (2021) Vol. 144, Iss. 3, pp. 229-235
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top